Report cover image

Leo Pharma AS - Strategic SWOT Analysis Review

Publisher GlobalData
Published Mar 31, 2026
Length 45 Pages
SKU # GBDT21065874

Description

Leo Pharma AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

LEO Pharma AS (LEO Pharma), a subsidiary of LEO Foundation, is a pharmaceutical company. It focuses on medical dermatology and specialized treatments. The company is developing therapies for skin conditions such as psoriasis, eczema, acne, and infections, alongside providing anticoagulant treatments for cancer patients. LEO Pharma’s pipeline includes delgocitinib, tralokinumab, spesolimab calcipotriol and betamethasone dipropionate, temtokibart, IL-1RAcP, STAT65, topical STAT6 delgocitinib for chronic hand eczema, TMB-001 for congenital ichthyosis, and temtokibart for atopic dermatitis. It is also advancing anti-inflammatory candidates in immunology, including LEO 158968 and LP0128. The company operates manufacturing sites and collaborates with contract manufacturers and API suppliers to ensure a reliable product supply for its treatments. LEO Pharma is headquartered in Ballerup, Denmark.

Leo Pharma AS Key Recent Developments

Mar 27,2026: LEO Pharma Presents Long-Term Data on SPEVIGO for Adults With Generalized Pustular Psoriasis
Mar 20,2026: LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real-World Evidence, Long-Term Outcomes and Patient Experience
Feb 23,2026: LEO Pharma to Nominate Kasper Fangel as Board Member and Audit Committee Chair
Feb 18,2026: LEO Pharma Reports 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note:Some sections may be missing if data is unavailable for the company.

Table of Contents

45 Pages
Section 1 - About the Company
Leo Pharma AS - Key Facts
Leo Pharma AS - Key Employees
Leo Pharma AS - Key Employee Biographies
Leo Pharma AS - Major Products and Services
Leo Pharma AS - History
Leo Pharma AS - Company Statement
Leo Pharma AS - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Leo Pharma AS - Business Description
Geographical Segment: Europe
Performance
Geographical Segment: North America
Performance
Geographical Segment: Rest of World
Performance
Leo Pharma AS - Corporate Strategy
Leo Pharma AS - SWOT Analysis
SWOT Analysis - Overview
Leo Pharma AS - Strengths
Leo Pharma AS - Weaknesses
Leo Pharma AS - Opportunities
Leo Pharma AS - Threats
Leo Pharma AS - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Leo Pharma AS, Recent Deals Summary
Section 4 – Company’s Recent Developments
Mar 27, 2026: LEO Pharma Presents Long-Term Data on SPEVIGO for Adults With Generalized Pustular Psoriasis
Mar 20, 2026: LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real-World Evidence, Long-Term Outcomes and Patient Experience
Feb 23, 2026: LEO Pharma to Nominate Kasper Fangel as Board Member and Audit Committee Chair
Feb 18, 2026: LEO Pharma Reports 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin
Jan 23, 2026: LEO Pharma Presents Twenty-Three Posters at Maui Derm Hawaii 2026, Demonstrating Continued Commitment to Scientific Innovation in Medical Dermatology
Jan 23, 2026: LEO Pharma to Present 23 Posters at Maui Derm Hawaii 2026
Dec 16, 2025: LEO Pharma Names Marika Murto Senior Vice President, Global Product Strategy
Dec 15, 2025: LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo to EMA
Nov 06, 2025: LEO Pharma Delivers 8% Revenue Growth at CER in 9M 2025 and Updates Full-Year Outlook
Nov 05, 2025: LEO Pharma Receives NICE Recommendation for Reimbursement in England and Wales
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Leo Pharma AS, Key Facts
Leo Pharma AS, Key Employees
Leo Pharma AS, Key Employee Biographies
Leo Pharma AS, Major Products and Services
Leo Pharma AS, History
Leo Pharma AS, Subsidiaries
Leo Pharma AS, Key Competitors
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
Leo Pharma AS, Recent Deals Summary
List of Figures
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
Leo Pharma AS, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us